Acute On Chronic Liver Failure Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute On Chronic Liver Failure pipeline constitutes 3+ key companies continuously working towards developing 5+ Acute On Chronic Liver Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute On Chronic Liver Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acute On Chronic Liver Failure Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute On Chronic Liver Failure Market.

Some of the key takeaways from the Acute On Chronic Liver Failure Pipeline Report: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Acute On Chronic Liver Failure treatment therapies with a considerable amount of success over the years.
• Acute On Chronic Liver Failure companies working in the treatment market are Grifols Therapeutics, GENFIT, Yaqrit, GENFI, Cellaion, Grifols Therapeutics, and others, are developing therapies for the Acute On Chronic Liver Failure treatment
• Emerging Acute On Chronic Liver Failure therapies in the different phases of clinical trials are- ALBUTINE (Albumin 5%), Nitazoxanide, TAK-242, VS-01, HepaStem, SMT + PE-A 5%, and others are expected to have a significant impact on the Acute On Chronic Liver Failure market in the coming years.
• In March 2026, GENFIT (Euronext: GNFT), a biopharmaceutical company focused on advancing treatments for rare and life-threatening liver conditions, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NTZ (nitazoxanide). This investigational small-molecule therapy is being developed in a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF). G1090N represents GENFIT's lead development program in the ACLF segment of its pipeline. The FDA's ODD highlights the potential of G1090N's active component to address this serious and rare condition, which is marked by rapid clinical decline, systemic inflammation, and high short-term mortality.
• In September 2025, GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company focused on enhancing the lives of patients with rare and severe liver diseases, announced today that it will discontinue the VS-01 program in ACLF (Acute-on-Chronic Liver Failure) and instead shift its focus to developing VS-01 for UCD (Urea Cycle Disorder).
• In April 2025, eGenesis, a biotech company focused on developing human-compatible engineered organs for patients with organ failure, and OrganOx Ltd., a leader in organ medical technology, announced that the U.S. FDA has approved the investigational new drug (IND) application for EGEN-5784. This human-compatible, genetically engineered porcine liver is intended for use alongside the OrganOx extracorporeal liver cross-circulation (ELC) system to treat patients with acute-on-chronic liver failure (ACLF) experiencing decompensated liver function in intensive care settings.
• In February 2025, Genfit Biopharma announced that alongside the expected Phase II results from the UNVEIL-IT trial assessing VS-01 in the second half of this year, it also plans to share up to three additional clinical datasets from its ACLF pipeline by the end of 2025.
• The US FDA has granted Orphan Drug Designation (ODD) to VS-01 for the treatment of ACLF.
• In March 2024, HepaRegeniX GmbH, a clinical-stage company focused on developing regenerative therapies for acute and chronic liver diseases, has published clinical and preclinical findings on its first-in-class MKK4 inhibitor, HRX-215, in the journal Cell. The study, available online (DOI: 10.1016/j.cell.2024.02.023), highlights HRX-215's ability to significantly enhance liver regeneration and prevent liver failure in preclinical models. Additionally, a first-in-human trial demonstrated its safety and tolerability. HRX-215 is a small molecule inhibitor targeting Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Acute On Chronic Liver Failure Overview
Acute-on-Chronic Liver Failure (ACLF) is a serious condition in which a person with pre-existing chronic liver disease experiences sudden and severe worsening of liver function. This rapid decline often leads to complications such as jaundice, bleeding, infections, or multi-organ failure. ACLF has a high risk of mortality and typically requires urgent medical care, with liver transplantation being a potential life-saving option in severe cases.

Get a Free Sample PDF Report to know more about Acute On Chronic Liver Failure Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Acute On Chronic Liver Failure Drugs Under Different Phases of Clinical Development Include:
• ALBUTINE (Albumin 5%): Grifols Therapeutics
• Nitazoxanide: GENFIT
• TAK-242: Yaqrit
• VS-01: GENFIT
• HepaStem: Cellaion
• SMT + PE-A 5%: Grifols Therapeutics

Acute On Chronic Liver Failure Route of Administration
Acute On Chronic Liver Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Acute On Chronic Liver Failure Molecule Type
Acute On Chronic Liver Failure Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Acute On Chronic Liver Failure Pipeline Therapeutics Assessment
• Acute On Chronic Liver Failure Assessment by Product Type
• Acute On Chronic Liver Failure By Stage and Product Type
• Acute On Chronic Liver Failure Assessment by Route of Administration
• Acute On Chronic Liver Failure By Stage and Route of Administration
• Acute On Chronic Liver Failure Assessment by Molecule Type
• Acute On Chronic Liver Failure by Stage and Molecule Type

DelveInsight's Acute On Chronic Liver Failure Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute On Chronic Liver Failure product details are provided in the report. Download the Acute On Chronic Liver Failure pipeline report to learn more about the emerging Acute On Chronic Liver Failure therapies
https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Acute On Chronic Liver Failure Therapeutics Market include:
Key companies developing therapies for Acute On Chronic Liver Failure are - RHEACELL, Versantis, Martin Pharmaceuticals, Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, Cipla, and others.

Acute On Chronic Liver Failure Pipeline Analysis:
The Acute On Chronic Liver Failure pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute On Chronic Liver Failure with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute On Chronic Liver Failure Treatment.
• Acute On Chronic Liver Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute On Chronic Liver Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute On Chronic Liver Failure market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute On Chronic Liver Failure drugs and therapies
https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute On Chronic Liver Failure Pipeline Market Drivers
• Increase in the prevalence of liver diseases, increase in the number of research and development activities are some of the important factors that are fueling the Acute On Chronic Liver Failure Market.

Acute On Chronic Liver Failure Pipeline Market Barriers
• However, side-effects associated with the treatment of Acute On Chronic Liver Failure (ACLF), high cost associated with the treatment and other factors are creating obstacles in the Acute On Chronic Liver Failure Market growth.

Scope of Acute On Chronic Liver Failure Pipeline Drug Insight
• Coverage: Global
• Key Acute On Chronic Liver Failure Companies: Grifols Therapeutics, GENFIT, Yaqrit, GENFI, Cellaion, Grifols Therapeutics, and others
• Key Acute On Chronic Liver Failure Therapies: ALBUTINE (Albumin 5%), Nitazoxanide, TAK-242, VS-01, HepaStem, SMT + PE-A 5%, and others
• Acute On Chronic Liver Failure Therapeutic Assessment: Acute On Chronic Liver Failure current marketed and Acute On Chronic Liver Failure emerging therapies
• Acute On Chronic Liver Failure Market Dynamics: Acute On Chronic Liver Failure market drivers and Acute On Chronic Liver Failure market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.